BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JSKN016 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JSKN016\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07493980-2147@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:JSKN016: Phase 2 readout est. (NCT07493980)
DESCRIPTION:JSKN016\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study o
 n the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable 
 Stage II-III Non-small Cell Lung Cancer Patients\nEstimated primary comple
 tion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/j
 skn016#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07493980
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-2147@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JSKN016: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:JSKN016\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or 
 Metastatic HER2-Negative Breast Cancer\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jskn016#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0694223
 4
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775483-2147@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JSKN016: Phase 2 readout est. (NCT06775483)
DESCRIPTION:JSKN016\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Evaluat
 ion of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a
  Phase II Clinical Study\nEstimated primary completion: 30 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/jskn016#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06775483
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336771-2147@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JSKN016: Phase 1/2 readout est. (NCT07336771)
DESCRIPTION:JSKN016\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic H
 R-Positive\, HER2-Negative Breast Cancer\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jskn016#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 6771
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868732-2147@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:JSKN016: Phase 1 readout est. (NCT06868732)
DESCRIPTION:JSKN016\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Evaluat
 ion of JSKN016 Combination Therapy in Subjects With NSCLC\nEstimated prima
 ry completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/jskn016#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06868732
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533123-2147@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20290317
DTEND;VALUE=DATE:20290318
SUMMARY:JSKN016: Phase 3 readout est. (NCT07533123)
DESCRIPTION:JSKN016\, phase 3.\nStudy: A Phase III Study of JSKN016 Versus 
 Treatment of Physician's Choice in Patients With Triple-Negative Breast Ca
 ncer Who Have Failed Standard of Care\nEstimated primary completion: 17 Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jskn016#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0753312
 3
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
